$PVCT: #Godzilla ($PFE) Vs. #Mothra

A blog reader and frequent e-mailer sent me this article: Is AstraZeneca getting ready to buy a pipeline? by FierceBiotech's John Carroll. Thank you.

The story comes from Reuter's Ben Hirschler's article New AstraZeneca CEO plans to invest through tough year. A notable quote:

After reading both of the articles, I could not help but think of Craig's comments and related presentation slide at the Noble conference.

Godzilla versus Mothra?

Let's get it on!

$PVCT: And Behind Door #4...

What was Craig saying when he showed this slide during his Noble presentation?

I think the current guidance of an SPA receipt sometime in Q1 remains. The start of the MM Phase III trial is, of course, a function of the receipt of the SPA; that is, the trial should commence about 30 days (maybe less) after an SPA PR.

$PVCT: Noble Financial Capital Markets Ninth Annual Equity Conference (update)

A webcast of Craig's presentation is here.

$PVCT: Noble Financial Capital Markets Ninth Annual Equity Conference (update)

Provectus released Craig's conference slides today. See here.

This slide (below) highlights what to potentially or possibly look out for this month and quarter. It also appears to confirm the rumor another Big Pharma company approached the company with interest in a global license for PV-10.

This slide (below) highlights several very under-appreciated aspects of the new rose bengal synthesis patent application and process.

$PVCT: Noble Financial Capital Markets Ninth Annual Equity Conference

Management will be presenting at the above conference on January 22.